Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

, MRK

Merck

$83.81

-1.8 (-2.10%)

14:51
07/08/19
07/08
14:51
07/08/19
14:51

BeyondSpring CEO sees neutropenia increasing as chemotherapy is used more

BeyondSpring (BYSI) is a global biopharmaceutical company focused on the development of innovative cancer therapies. In an exclusive interview with The Fly, CEO Lan Huang discussed Plinabulin and chemotherapy as a treatment: "I think this business model is innovative and it would be good for the public to understand and support it. There may be some potential misconceptions around the company. Plinabulin comes from nature and may not be well known. By understanding the mechanism as an immune-oncology agent, we are able to use Plinabulin much better. So that's why we selected this target population for the anti-cancer indication in our Wall Street study, which is lung cancer. Secondly, as a new agent it also can protect the stem cells in the bone marrow and it's also a complimentary in the mechanism with G-CSF. That's why we're combining with G-CSF for the CIN indication. If people look at our presentations, then they would understand plinabulin mechanism as IO agent. And maybe we can also do triple combos. Another potential misconception is with IO coming to the field, people feel like chemotherapy is probably going to go away, but actually it's not. Recent publications show that from now to 2040, chemotherapy is actually going to increase with [Merk's (MRK)] Keytruda and chemo being approved in the first line, and Roche's [RHHBY] PD-L1 approved in the small cell lung cancer. With that new development of chemo with PD-1, chemo is going to be used a lot more and with that there will be more CIN. That CIN market is not going to decrease, it's going to increase. That would be good for plinabulin because plinabulin is targeting the broad CIN indication and the label is for all chemo and all cancer." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

RHHBY

Roche

$0.00

(0.00%)

MRK

Merck

$83.81

-1.8 (-2.10%)

BYSI

BeyondSpring

$20.20

-0.13 (-0.64%)

  • 16

    Jul

  • 25

    Jul

  • 30

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 02

    Sep

  • 09

    Sep

  • 16

    Sep

  • 20

    Sep

  • 02

    Oct

  • 04

    Nov

RHHBY Roche
$0.00

(0.00%)

06/28/19
PIPR
06/28/19
DOWNGRADE
Target $250
PIPR
Neutral
Biogen downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond downgraded Biogen (BIIB) to Neutral from Overweight and lowered his price target for the shares to $250 from $280. The stock closed yesterday up $1.70 to $239.77. Piper's new neurologist survey data from Spherix Global Insights "spells bad news for both Tecfidera and Tysabri in the near and longer term," Raymond tells investors in a research note. For the first time in a long time, Tecfidera market share is projected to contract over the next six months, primarily at the hands of Novartis' (NVS) new entrant Mayzent, explains the analyst. Further, Raymond notes that while prior surveys have indicated a plateauing of Roche's (RHHBY) Ocrevus with Biogen's Tysabri "hanging in there," the most recent indications are for an accelerating Ocrevus with Tysabri the "clear loser." The analyst lowered his estimates for both Tecfidera and Tysabri and downgraded Biogen.
06/21/19
WBLR
06/21/19
NO CHANGE
WBLR
Outperform
William Blair an 'aggressive' buyer of Exelixis on weakness from clinical miss
William Blair analyst Andy Hsieh is an "aggressive" buyer of Exelixis (EXEL) shares on weakness after the company's partner Roche (RHHBY) informed the company that the Phase III IMspire170 trial, which assesses the safety and efficacy of the combination of Cotellic and Tecentriq, did not meet the primary endpoint of progression-free survival in treatment-naive melanoma. Hsieh says that while the news is disappointing, he reiterates that his bullish thesis resides in Exelixis's growth potential, driven by the Cabometyx franchise. As a result, the melanoma clinical setback does not impact the analyst's stock outlook. Further, he points out that he and the Street have not modeled revenue contribution from the IMspire170 study. Hsieh keeps an Outperform rating on Exelixis.
06/20/19
LIBR
06/20/19
DOWNGRADE
LIBR
Hold
Roche downgraded to Hold from Buy at Liberum
Liberum analyst Graham Doyle downgraded Roche to Hold from Buy with a price target of 275 francs. The analyst says the shares are "no longer in bargain territory" and that there are a lack of catalysts to move them higher.
06/20/19
DBAB
06/20/19
UPGRADE
DBAB
Buy
Roche upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Richard Parkes upgraded Roche to Buy from Hold saying the company's portfolio and pipeline should offset upcoming U.S. biosimilar launches. The analyst sees upside to consensus estimates.
MRK Merck
$83.81

-1.8 (-2.10%)

06/21/19
BOFA
06/21/19
NO CHANGE
Target $96
BOFA
Buy
Merck price target raised to $96 from $91 at BofA/Merrill
BofA/Merrill Lynch analyst Jason Gerberry raised his price target on Merck shares to $96 from $91 following the company's investor day meeting, stating that management conveyed a slightly more bullish outlook on margins and key revenue growth drivers at the event. He now thinks Merck will achieve about 40% operating margins by 2023, up from his prior 37.5% view, and also raised his out-year Gardasil estimates and factored in V114 risk-adjusted peak sales at $0.8B following the meeting. Gerberry keeps a Buy rating on Merck shares.
07/02/19
MZHO
07/02/19
INITIATION
Target $97
MZHO
Buy
Merck initiated with a Buy at Mizuho
Mizuho started Merck with a Buy rating and $97 price target.
07/03/19
MZHO
07/03/19
INITIATION
Target $97
MZHO
Buy
Mizuho starts Merck with Buy rating, $97 price target
Mizuho analyst Mara Goldstein last night initiated coverage of Merck with a Buy rating and $97 price target. The company is larger than Keytruda, but the "drug is too big to ignore," Goldstein tells investors in a research note. She believes Merck can overcome the loss of exclusivity on its Januvia franchise given Keytruda's "dominance" in immuno-oncology. The latter will drive operating margin expansion over the next five years, contends Goldstein.
07/03/19
07/03/19
NO CHANGE

Fly Intel: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. Gol Linhas (GOL) upgraded to Buy from Neutral at Goldman Sachs with analyst Bruno Amorim saying the suspension of Avianca Brasil's operations on May 24 should provide a "significant boost" to unit revenues in the Brazilian domestic market in upcoming quarters. 2. Cinemark (CNK) upgraded to Buy from Hold at Loop Capital with analyst Alan Gould saying the "tough" comp facing the company in Q2 is now priced into the shares. 3. Latam Airlines (LTM) downgraded to Sell from Neutral at Goldman Sachs with analyst Bruno Amorim saying "fierce" competition in the Spanish speaking countries and "still weak" pricing in the international markets will likely offset the positive effect from Avianca Brasil's bankruptcy. 4. Inogen (INGN) downgraded to Underweight from Neutral at JPMorgan with analyst Robert Marcus, who continues to view Inogen as a "potentially attractive story" longer-term, saying he believes the company's near-term outlook is weighed down by uncertainty and market headwinds. 5. Merck (MRK) initiated with a Buy rating and a $97 price target at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BYSI BeyondSpring
$20.20

-0.13 (-0.64%)

04/30/19
MAXM
04/30/19
DOWNGRADE
MAXM
Hold
BeyondSpring downgraded to Hold from Buy at Maxim
04/30/19
HCWC
04/30/19
NO CHANGE
HCWC
BeyondSpring 'investment thesis remains strong,' says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $60 price target on BeyondSpring, noting that the company has delivered important and positive data readouts through 2018, which support "the potential use of plinabulin in combination with SoC to treat CIN with a special focus on improving bone pain." The analyst also sees upcoming catalysts for BeyondSpring coming from "crucial updates on all clinical programs" throughout the year at medical conferences, likely ASCO, SITC, and ASH 2019.
12/06/18
HCWC
12/06/18
NO CHANGE
HCWC
BeyondSpring delivers important milestone, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy and $60 price target on BeyondSpring after the company posted that its pivotal Phase 3 study 105 interim analysis met its primary endpoint in the head-to head study of Plinabulin vs. Neulasta, as single agent, in cancer patients undergoing chemotherapy. The analyst called this "an important milestone," and noted that as a result of these positive outcomes along with the recent data released at ASH 2018 from the Phase 2 106 study, the company is now ready to submit to the China FDA an NDA for deploying Plinabulin to treat CIN in cancer patients.

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$298.86

1.07 (0.36%)

, SPX

S&P 500

$0.00

(0.00%)

20:32
07/18/19
07/18
20:32
07/18/19
20:32
General News
Trump to nominate Gene Scalia as Secretary of Labor »

President Trump tweeted:…

SPY

SPDR S&P 500 ETF Trust

$298.86

1.07 (0.36%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXP

American Express

$128.40

1.355 (1.07%)

, BLK

BlackRock

$474.98

4.06 (0.86%)

20:25
07/18/19
07/18
20:25
07/18/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

AXP

American Express

$128.40

1.355 (1.07%)

BLK

BlackRock

$474.98

4.06 (0.86%)

SLB

Schlumberger

$38.78

0.15 (0.39%)

SYF

Synchrony

$36.09

0.54 (1.52%)

STT

State Street

$56.27

1.67 (3.06%)

CFG

Citizens Financial

$34.62

0.27 (0.79%)

RF

Regions Financial

$14.76

0.06 (0.41%)

KSU

Kansas City Southern

$118.03

1.22 (1.04%)

ALV

Autoliv

$69.88

0.04 (0.06%)

GNTX

Gentex

$23.54

0.01 (0.04%)

MAN

ManpowerGroup

$90.30

0.82 (0.92%)

CLF

Cleveland-Cliffs

$10.88

-0.11 (-1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 06

    Aug

  • 06

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 27

    Aug

  • 27

    Oct

  • 13

    Nov

POST

Post Holdings

$108.09

0.64 (0.60%)

20:12
07/18/19
07/18
20:12
07/18/19
20:12
Upgrade
Post Holdings rating change at Piper Jaffray »

Post Holdings upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

VMW

VMware

$174.34

0.13 (0.07%)

19:01
07/18/19
07/18
19:01
07/18/19
19:01
Hot Stocks
VMware to acquire Bitfusion, terms not disclosed »

In a blog post, VMware…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

CRWD

Crowdstrike

$72.75

1.77 (2.49%)

, SKX

Skechers

$34.75

0.35 (1.02%)

18:50
07/18/19
07/18
18:50
07/18/19
18:50
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

CRWD

Crowdstrike

$72.75

1.77 (2.49%)

SKX

Skechers

$34.75

0.35 (1.02%)

EXPO

Exponent

$61.63

0.83 (1.37%)

MSFT

Microsoft

$136.29

0.06 (0.04%)

CHWY

Chewy

$32.79

1.14 (3.60%)

RRGB

Red Robin

$30.58

0.32 (1.06%)

GCI

Gannett

$7.90

-0.185 (-2.29%)

IFRX

InflaRx

$3.12

0.05 (1.63%)

BA

Boeing

$361.17

-8.28 (-2.24%)

MVIS

MicroVision

$0.86

0.0458 (5.62%)

OZK

Bank OZK

$28.61

0.5 (1.78%)

ISRG

Intuitive Surgical

$536.44

13.25 (2.53%)

AA

Alcoa

$23.42

0.27 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 19

    Jul

  • 23

    Jul

  • 24

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 26

    Aug

  • 26

    Aug

  • 09

    Sep

  • 23

    Sep

  • 16

    Oct

MGM

MGM Resorts

$28.75

-0.095 (-0.33%)

, MGP

MGM Growth

$30.00

-0.06 (-0.20%)

18:50
07/18/19
07/18
18:50
07/18/19
18:50
Periodicals
MGM said to consider sale-leaseback of Bellagio, MGM Grand, Bloomberg says »

The report states the…

MGM

MGM Resorts

$28.75

-0.095 (-0.33%)

MGP

MGM Growth

$30.00

-0.06 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 06

    Aug

AAL

American Airlines

$33.75

0.5 (1.50%)

, UAL

United Continental

$95.27

0.44 (0.46%)

18:49
07/18/19
07/18
18:49
07/18/19
18:49
Periodicals
POTUS meets with U.S. airlines over Qatar subsidy accusations, Reuters says »

U.S. President Donald…

AAL

American Airlines

$33.75

0.5 (1.50%)

UAL

United Continental

$95.27

0.44 (0.46%)

JBLU

JetBlue

$19.23

0.14 (0.73%)

FDX

FedEx

$165.39

0.375 (0.23%)

AAWW

Atlas Air

$42.58

0.79 (1.89%)

BA

Boeing

$361.17

-8.28 (-2.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 01

    Aug

  • 17

    Sep

  • 13

    Nov

  • 14

    Nov

NUE

Nucor

$54.68

-0.03 (-0.05%)

18:44
07/18/19
07/18
18:44
07/18/19
18:44
Hot Stocks
Nucor CEO: We are very pleased with the results from the tariffs »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

NABZY

National Australia Bank

$0.00

(0.00%)

18:30
07/18/19
07/18
18:30
07/18/19
18:30
Hot Stocks
National Australia Bank names Ross McEwan as new CEO »

National Australia Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$29.48

0.3 (1.03%)

18:22
07/18/19
07/18
18:22
07/18/19
18:22
Hot Stocks
Bank of America CEO: Millennials are a huge customer base for us »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

  • 06

    Sep

  • 16

    Oct

TAP

Molson Coors

$54.37

0.08 (0.15%)

18:06
07/18/19
07/18
18:06
07/18/19
18:06
Hot Stocks
Molson Coors raises quarterly dividend to 57c from 41c per share »

Molson Coors declared a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

MSFT

Microsoft

$136.29

0.06 (0.04%)

18:04
07/18/19
07/18
18:04
07/18/19
18:04
Hot Stocks
Breaking Hot Stocks news story on Microsoft »

Microsoft up over 2%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

BAS

Basic Energy

$1.81

-0.1 (-5.24%)

18:02
07/18/19
07/18
18:02
07/18/19
18:02
Hot Stocks
Basic Energy announces record setting lateral completion in Permian Basin »

Basic Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 13

    Nov

MSFT

Microsoft

$136.29

0.06 (0.04%)

18:02
07/18/19
07/18
18:02
07/18/19
18:02
Hot Stocks
Microsoft CFO continues to expect double digit revenue growth in FY20 »

Sees FY20 operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

QTRH

Quarterhill

$1.23

(0.00%)

18:02
07/18/19
07/18
18:02
07/18/19
18:02
Hot Stocks
WiLAN unit acquires patent portfolio from Vidiator »

Wi-LAN announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$136.29

0.06 (0.04%)

18:00
07/18/19
07/18
18:00
07/18/19
18:00
Earnings
Microsoft sees total Q1 revenue at implied $31.7B-$32.4B, consensus $32.0B »

By segment: Sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

RRGB

Red Robin

$30.58

0.32 (1.06%)

18:00
07/18/19
07/18
18:00
07/18/19
18:00
Hot Stocks
Red Robin up 17% after confirming $40.00 per share offer from Vintage Capital »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$33.09

-0.17 (-0.51%)

17:54
07/18/19
07/18
17:54
07/18/19
17:54
Periodicals
AT&T mulls sale of Puerto Rican business to pay down debt, Bloomberg says »

AT&T, which is eyeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 30

    Jul

  • 08

    Aug

RRGB

Red Robin

$30.58

0.32 (1.06%)

17:53
07/18/19
07/18
17:53
07/18/19
17:53
Hot Stocks
Red Robin confirms $40.00 per share cash buyout proposal from Vintage Capital »

Red Robin confirmed it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$136.29

0.06 (0.04%)

17:50
07/18/19
07/18
17:50
07/18/19
17:50
Hot Stocks
Microsoft CFO: Q4 another quarter of double-digit top and bottom line growth »

Says commercial bookings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

HBIO

Harvard Bioscience

$1.78

0.03 (1.71%)

17:46
07/18/19
07/18
17:46
07/18/19
17:46
Hot Stocks
Harvard Bioscience names Michael Rossi CFO »

Harvard Bioscience has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$136.29

0.06 (0.04%)

17:43
07/18/19
07/18
17:43
07/18/19
17:43
Hot Stocks
Microsoft CEO seeing growing momentum across every layer of its stack »

Says LinkedIn saw record…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

ISRG

Intuitive Surgical

$536.44

13.25 (2.53%)

17:38
07/18/19
07/18
17:38
07/18/19
17:38
Hot Stocks
Intuitive Surgical falls after Q2 report, despite earnings beat »

Shares of Intuitive are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Aug

  • 09

    Sep

GLD

SPDR Gold Shares

$136.44

1.85 (1.37%)

17:33
07/18/19
07/18
17:33
07/18/19
17:33
Hot Stocks
SPDR Gold Shares holdings rise to 814.62MT from 803.18MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAL

Western Alliance

$44.45

0.74 (1.69%)

17:29
07/18/19
07/18
17:29
07/18/19
17:29
Earnings
Western Alliance reports Q2 EPS 1.19, consensus $1.16 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 06

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.